Format

Send to

Choose Destination
Clin Cancer Res. 2017 Feb 1;23(3):857-867. doi: 10.1158/1078-0432.CCR-16-0290. Epub 2016 Aug 15.

Recurrent TRIO Fusion in Nontranslocation-Related Sarcomas.

Author information

1
Inserm U916, Bergonié Cancer Institute, Bordeaux, France.
2
University of Bordeaux, Bordeaux, France.
3
Department of Pathology, Bergonié Cancer Institute, Bordeaux, France.
4
Department of Pathology, University Cancer institute Toulouse-Oncopole, Toulouse, France.
5
Department of Pathology, Gustave Roussy Institute, Villejuif, France.
6
Department of Pathology, Léon Bérard Center, Lyon, France.
7
Centre de Recherche en Biologie Cellulaire de Montpellier, CRBM, CNRS-UMR 5237, University of Montpellier, Montpellier, France.
8
Inserm U916, Bergonié Cancer Institute, Bordeaux, France. F.chibon@bordeaux.unicancer.fr.

Abstract

PURPOSE:

Despite various differences, nontranslocation-related sarcomas (e.g., comprising undifferentiated pleomorphic sarcoma, leiomyosarcoma, myxofibrosarcoma) are unified by their complex genetics. Extensive analysis of the tumor genome using molecular cytogenetic approaches showed many chromosomal gains, losses, and translocations per cell. Genomic quantitative alterations and expression variations have been extensively studied by adapted high-throughput approaches, yet translocations still remained unscreened. We therefore analyzed 117 nontranslocation-related sarcomas by RNA sequencing to identify fusion genes.

EXPERIMENTAL DESIGN:

We performed RNA sequencing and applied a bioinformatics pipeline dedicated to the detection of fusion transcripts. RT-PCR and Sanger sequencing were then applied to validate predictions and to search for recurrence and specificity.

RESULTS:

Among the 6,772 predicted fusion genes, 420 were in-frame. One recurrent rearrangement, consistently involving TRIO with various partners, was identified in 5.1% of cases. TRIO translocations are either intrachromosomal with TERT or interchromosomal with LINC01504 or ZNF558 Our results suggest that all translocations led to a truncated TRIO protein either directly or indirectly by alternative splicing. TRIO rearrangement is associated with a modified transcriptomic program to immunity/inflammation, proliferation and migration, and an increase in proliferation.

CONCLUSIONS:

TRIO fusions have been identified in four different sarcoma histotypes, likely meaning that they are not related to a primary oncogenic event but rather to a secondary one implicated in tumor progression. Moreover, they appear to be specific to nontranslocation-related sarcomas, as no such rearrangement was identified in sarcomas with simple genetics. More cases could lead to a significant association of these fusions to a specific clinical behavior. Clin Cancer Res; 23(3); 857-67. ©2016 AACR.

PMID:
27528700
DOI:
10.1158/1078-0432.CCR-16-0290
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center